Open Access

REVIEW

Nuclear–Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance

Xueping Zhu^1,2,3,#, Misi He^1,2,3,#, Ling Wang^1,2,3,#, Rui Su⁴, Lin Zhong^1,2,3, Ting Guo^1,2,3,4, Haixia Wang^1,2,3,*, Dongling Zou^1,2,3,*

1 Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing Cancer Institute, Chongqing Cancer Hospital, Chongqing, China
2 Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China
3 Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China
4 Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA

* Corresponding Authors: Haixia Wang. Email: ; Dongling Zou. Email:
# These authors contributed equally to this work

(This article belongs to the Special Issue: Molecular Targeting Therapy for Anticancer Treatment)

Oncology Research 2026, 34(9), 11 https://doi.org/10.32604/or.2026.083902

Received 13 April 2026; Accepted 11 June 2026; Issue published 13 August 2026

Abstract

Nucleocytoplasmic transport (NCT) regulates the spatial distribution of proteins and RNA between the nucleus and cytoplasm. NCT dysregulation can mislocalize tumor suppressors, DNA-repair factors, transcription factors, and drug targets in cancer. In this review, we conceptualize NCT-dependent protein mislocalization as a spatial regulatory framework for anticancer drug resistance, rather than as a catalogue of transport components. We systematically discuss how nuclear pore complex (NPC) remodeling, transport-receptor imbalance, post-translational modification (PTM)-regulated cargo routing, signaling-NCT crosstalk, nuclear localization signal/nuclear export signal (NLS/NES) alterations, and tumor microenvironmental pressures jointly drive aberrant nucleocytoplasmic distribution. These processes can further regulate apoptosis, DNA-damage repair, oncogenic transcription, oxidative stress adaptation and drug-target accessibility, which ultimately promote drug tolerance and therapeutic resistance. We further distinguish clinically validated mechanisms from preclinical phenotypes and correlative observations. At present, the most advanced therapeutic evidence mainly supports exportin 1/chromosome region maintenance 1 (XPO1/CRM1) inhibition, particularly selinexor in selected hematologic malignancies; in contrast, strategies targeting the NPC, importins, PTM pathways, microenvironmental cues, or localization signals remain largely investigational. By integrating mechanistic, preclinical, translational, and clinical evidence, this review aims to synthesize current evidence on NCT-dependent protein mislocalization as a resistance-relevant axis and to highlight the need for cargo-specific biomarkers and rational combination strategies to translate this biology into anticancer therapy.

---

Keywords

---

Supplementary Material

Supplementary Material File

---